BioMarin Pharmaceuticals
BMRN
519 hedge funds and large institutions have $16.1B invested in BioMarin Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 191 increasing their positions, 192 reducing their positions, and 76 closing their positions.
60% more call options, than puts
Call options by funds: $139M | Put options by funds: $86.9M
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
1.23% more ownership
Funds ownership: 95.22% → 96.45% (+1.2%)
4% more capital invested
Capital invested by funds: $15.5B → $16.1B (+$564M)
1% less repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 192
7% less funds holding
Funds holding: 558 → 519 (-39)
43% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$259M |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$253M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$76.6M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$70.6M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$52.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$113M |
| 2 |
CG
Carmignac Gestion
Paris,
France
|
-$96.3M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$65.7M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$53.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$47.7M |
BMRN Hedge Fund Activity: Q3 2023 in Review
519 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2023, worth a combined $16.1B — up 3.6% from $15.5B a quarter earlier.
Sellers outnumbered buyers: 76 funds closed out of BMRN and 43 opened new positions — a net loss of 33 holders — while 192 trimmed existing stakes and 191 added.
The largest buyer was Barclays, adding an estimated $259M. The largest seller was Bank of America, cutting an estimated $113M.
- 519 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2023, down from 558 in Q2 2023.
- Funds reported $16.1B of BioMarin Pharmaceuticals stock for Q3 2023, up 3.6% quarter-over-quarter.
- 43 funds opened new BioMarin Pharmaceuticals positions in Q3 2023 and 76 closed out, a net change of -33 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2023 was Barclays, an estimated $259M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2023 was Bank of America, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2023.